| Associated Funds |
Form D |
Role |
2011 - 2026 |
Raised |
AUM |
|
| Dualitas Therapeutics Inc |
021-564321
|
Director |
|
32.6 M
of 66.6 M |
|
| 20/20 Genesystems Inc |
021-539305
|
Director |
|
0.1 M
of 3.0 M |
|
| TREX Holdings Inc |
021-530561
|
Director |
|
42.3 M
of 85.0 M |
|
| Nice Recovery Systems LLC |
021-523958
|
Executive Officer |
|
3.5 M
of 3.5 M |
|
| Insurica Insurance Services LLC |
021-493569
|
Executive Officer |
|
83.5 M |
|
| Therini Bio Inc |
021-478843
|
Director |
|
74.9 M
of 80.8 M |
|
| Assurex Global Reinsurance Ltd |
021-477438
|
Director |
|
0.0 M
of 2.0 M |
|
| Andovia Inc |
021-473392
|
Director |
|
0.6 M
of 1.0 M |
|
| SV Life Sciences Fund IV CF LP |
021-438954
|
Executive Officer |
|
421.4 M
of 421.4 M |
|
| Eyebiotech Ltd |
021-410579
|
Executive Officer |
|
0.0 M
of 0.0 M |
|
| Joseph Ventures Allium I LLC Series C |
021-407385
|
Executive Officer |
|
0.5 M |
|
| Joseph Ventures Allium I LLC Series D |
021-407377
|
Executive Officer |
|
0.2 M |
|
| Xilio Therapeutics Inc |
021-390683
|
Director |
|
95.0 M
of 95.0 M |
|
| Xilio Therapeutics Inc |
021-387002
|
Director |
|
50.2 M
of 50.2 M |
|
| Joseph Ventures Allium I LLC Series A |
021-380944
|
Executive Officer |
|
0.3 M |
|
| Maine Crisp Company LLC |
021-379439
|
Executive Officer |
|
1.1 M
of 2.2 M |
|
| Assurex Global Reinsurance Ltd |
021-373148
|
Director |
|
0.0 M
of 1.0 M |
|
| Everee Inc |
021-365344
|
Executive Officer |
|
10.0 M
of 10.0 M |
|
| Virtuoso-Mccarran LLC |
021-353857
|
Director |
|
0.3 M
of 2.8 M |
|
| Nice Recovery Systems LLC |
021-351646
|
Executive Officer |
|
2.4 M
of 2.4 M |
|
| Jason Ryan |
021-349534
|
Executive Officer |
|
9.2 M
of 50.0 M |
|
| Therini Bio Inc |
021-339813
|
Director |
|
9.4 M
of 9.4 M |
|
| Everee Inc |
021-338726
|
Executive Officer |
|
3.4 M
of 3.5 M |
|
| Ribometrix Inc |
021-326066
|
Director |
|
15.0 M
of 30.0 M |
|
| Ophthotech Corp |
021-324993
|
Director |
|
11.4 M
of 11.7 M |
|
| Sutro Biopharma Inc |
021-314024
|
Director |
|
85.4 M
of 85.4 M |
|
| Fresco Foods Inc |
021-300885
|
Director |
|
0.7 M |
|
| Arsanis Inc |
021-300012
|
Director |
|
20.0 M
of 20.0 M |
|
| Caprocq Core Holdings LP |
021-299770
|
Director |
|
7.0 M
of 50.0 M |
|
| Avitide Inc |
021-289476
|
Director |
|
12.0 M
of 12.0 M |
|
| Deciphera Pharmaceuticals LLC |
021-288027
|
Director |
|
52.3 M
of 52.3 M |
|
| Arsanis Inc |
021-286233
|
Director |
|
45.5 M
of 50.5 M |
|
| Arsanis Inc |
021-262117
|
Director |
|
15.0 M
of 15.0 M |
|
| Arsanis Inc |
021-254201
|
Director |
|
4.0 M
of 4.0 M |
|
| Cervilenz Inc |
021-251985
|
Director |
|
1.8 M
of 1.8 M |
|
| Assurex Global Reinsurance Ltd |
021-250112
|
Director |
|
0.1 M
of 2.0 M |
|
| Deciphera Pharmaceuticals LLC |
021-248413
|
Director |
|
90.6 M
of 90.6 M |
|
| Avitide Inc |
021-245207
|
Director |
|
3.8 M
of 7.7 M |
|
| Catabasis Pharmaceuticals Inc |
021-236973
|
Director |
|
12.4 M
of 20.4 M |
|
| Rockspring Capital Texas Real Estate BD/Ria Partners LP |
021-235628
|
Executive Officer |
|
5.0 M
of 50.0 M |
|
| Avitide Inc |
021-218775
|
Director |
|
3.4 M
of 3.4 M |
|
| Thesan Pharmaceuticals Inc |
021-212387
|
Director |
|
17.4 M
of 49.5 M |
|
| Euclid Systems Corp |
021-209264
|
Executive Officer |
|
0.5 M
of 3.0 M |
|
| Catabasis Pharmaceuticals Inc |
021-206457
|
Director |
|
32.4 M
of 32.4 M |
|
| Arsanis Inc |
021-201235
|
Director |
|
20.0 M
of 20.0 M |
|
| Ophthotech Corp |
021-197362
|
Director |
|
16.7 M
of 50.0 M |
|
| Avitide Inc |
021-193359
|
Director |
|
1.4 M
of 1.4 M |
|
| Catabasis Pharmaceuticals Inc |
021-191213
|
Director |
|
9.2 M
of 9.2 M |
|
| Cervilenz Inc |
021-189531
|
Director |
|
2.0 M
of 2.9 M |
|
| Abcam PLC |
021-177421
|
Director |
|
77.0 M
of 77.0 M |
|
| Adimab LLC |
021-176042
|
Director |
|
13.8 M
of 13.8 M |
|
| Cervilenz Inc |
021-173835
|
Director |
|
2.0 M
of 3.0 M |
|
| Cervilenz Inc |
021-167477
|
Director |
|
3.5 M
of 3.5 M |
|
| Link Medicine Corp |
021-158672
|
Director |
|
4.8 M
of 4.8 M |
|
| Arsanis Inc |
021-154945
|
Director |
|
9.6 M
of 9.6 M |
|
| Adimab Inc |
021-151089
|
Director |
|
4.0 M
of 4.0 M |
|
| Balance Health Corp |
021-150537
|
Director |
|
0.5 M
of 0.5 M |
|
| Juvaris Bio Therapeutics Inc |
021-149574
|
Director |
|
0.8 M
of 2.0 M |
|
| Arsanis Inc |
021-148139
|
Director |
|
0.4 M
of 0.4 M |
|
| Renasant Corp |
021-145904
|
Executive Officer |
|
55.0 M
of 55.0 M |
|
| Cervilenz Inc |
021-144992
|
Director |
|
3.1 M
of 3.1 M |
|
| Link Medicine Corp |
021-141389
|
Director |
|
20.0 M
of 20.0 M |
|
| Catabasis Pharmaceuticals Inc |
021-140570
|
Director |
|
7.7 M
of 39.7 M |
|
| Makena Capital Associates Cayman L P |
021-92796
|
Director |
|
3,870.9 M |
|
| Makena Capital Aurora Splitter A LP |
021-92772
|
Director |
|
1,346.7 M |
|
| Makena Capital Aurora Splitter B LP |
021-92759
|
Director |
|
1,706.8 M |
|
| Makena Capital Splitter A L P |
021-89364
|
Director |
|
2,660.4 M |
|
| Makena Capital Splitter B L P |
021-89363
|
Director |
|
3,384.8 M |
|
| Makena Capital Associates US LP |
021-92771
|
Director |
|
13.01 B |
|
| Makena Capital US L P |
021-88395
|
Director |
|
2,846.3 M |
|
| Ikano Therapeutics Inc |
021-101585
|
Director |
|
0.9 M |
|
| Adimab Inc |
021-106179
|
Director |
|
8.2 M
of 8.2 M |
|
| Juvaris Bio Therapeutics Inc |
021-84205
|
Director |
|
15.1 M
of 25.1 M |
|
| Cervilenz Inc |
021-122668
|
Director |
|
4.0 M
of 4.0 M |
|
| Link Medicine Corp |
021-76287
|
Director |
|
40.0 M
of 40.0 M |
|
| Strength Capital Partners LLC |
| Americlean Holdings LLC |
021-271539
|
Executive Officer |
|
11.0 M
of 11.0 M |
6.0 M |
| SV Health Managers LLP |
| Dementia Discovery LP |
021-249408
|
Executive Officer |
|
26.0 M
of 302.4 M |
252.4 M |
| SV7 Impact Medicine Fund LP |
021-342712
|
Executive Officer |
|
of 250.0 M |
296.9 M |
| SV Health Investors LLC |
| DDF Parallel LLP |
021-249408
|
Executive Officer |
|
26.0 M
of 302.4 M |
19.3 M |
| SV Life Sciences Fund VI Strategic Partners LP |
021-284644
|
Executive Officer |
|
13.1 M
of 13.1 M |
8.7 M |
| SV Life Sciences Fund VI Strategic Partners LP |
021-284644
|
Executive Officer |
|
13.1 M
of 13.1 M |
13.3 M |
| Dementia Discovery LP |
021-249408
|
Executive Officer |
|
26.0 M
of 302.4 M |
169.6 M |
| SV Life Sciences Fund VI LP |
021-240550
|
Executive Officer |
|
273.5 M
of 400.0 M |
201.5 M |
| SV Life Sciences Fund V LP |
021-129520
|
Executive Officer |
|
407.2 M
of 500.0 M |
138.5 M |
| SV Life Sciences Fund V Strategic Partners LP |
021-140268
|
Executive Officer |
|
10.6 M
of 10.6 M |
4.1 M |
| Makena Capital Management LLC |
| Makena Capital Blocker Y Cayman LP |
021-128599
|
Director |
|
942.9 M |
1,632.8 M |
| Makena Capital Splitter M LP |
021-128588
|
Director |
|
593.3 M |
|
| Makena Capital Splitter Prime LP |
021-128589
|
Director |
|
65.8 M |
|
| Makena Capital Splitter X LP |
021-128590
|
Director |
|
4,152.5 M |
3,711.7 M |
| Makena Contingent Capital Account II LP |
021-137912
|
Promoter |
|
415.5 M
of 1,000.0 M |
|
| Makena Contingent Capital Account LP |
021-127175
|
Director |
|
372.5 M
of 372.5 M |
0.8 M |